Introduction

Dr. Kirsten Bibbons-Domingo: This is the JAMA Editor's Summary, a review of important research and review articles appearing in the latest JAMA issue. The first original research article is from Dr. Paggadipati and colleagues on coordinated care to optimize cardiovascular preventive therapies in patients with Type 2 diabetes. After six to 12 months, patients in the intervention group were significantly more likely to be prescribed all three therapies compared with the usual care group. A Phase 3 open-label randomized clinical trial investigated Panatuma Mab versus Bevacissumab when added to standard first-line chemotherapy.